Unknown

Dataset Information

0

Cardiopulmonary Exercise Testing Reflects Improved Exercise Capacity in Response to Treatment in Morquio A Patients: Results of a 52-Week Pilot Study of Two Different Doses of Elosulfase Alfa.


ABSTRACT: OBJECTIVE:To assess impact of a 52-week elosulfase alfa enzyme replacement therapy (ERT) on exercise capacity in Morquio A patients and analyze cardiorespiratory and metabolic function during exercise to uncover exercise limitations beyond skeletal abnormalities. METHODS:Morquio A patients aged ?7 years, able to walk >200 m in the 6-minute walk test (6MWT), received elosulfase alfa 2.0 mg/kg/week (N = 15) or 4.0 mg/kg/week (N = 10) for 52 weeks in the randomized, double-blind MOR-008 study ( ClinicalTrials.gov NCT01609062) and its extension. Exercise capacity was assessed by 6MWT, 3-minute stair climb test (3MSCT), and cardiopulmonary exercise test (CPET; N = 15 dosage groups combined). RESULTS:Changes over 52 weeks in 6MWT and 3MSCT were minimal. Baseline CPET results showed impaired weight-adjusted peak oxygen uptake (VO2), partly attributable to inability to increase tidal volume during exercise. CPET measures of exercise function showed significant improvement at 25 and/or 52 weeks in exercise duration, peak workload, O2 pulse, and peak tidal volume (% increases in duration, 16.9 (P = 0.0045) and 9.4 (P = 0.0807); peak workload, 26.5 (P = 0.0026) and 21.2 (P = 0.0132); O2 pulse, 10.7 (P = 0.0187) and 2.3 (P = 0.643); peak tidal volume, 11.7 (P = 0.1117) and 29.1 (P = 0.0142)). In addition, decreased VO2/work ratio was noted (% decrease -7.6 [-11.9, 1.3] and -9.2 [-25.7, 5.1]), indicating performance of work at reduced oxygen cost. CONCLUSIONS:CPET uncovers limitation in exercise capacity in Morquio A related to reduced lung function. ERT improves exercise capacity and efficiency of oxygen utilization, not attributable to changes in cardiac or pulmonary function. Further study of the long-term impact of ERT on exercise capacity and the clinical relevance of the observed changes is warranted.

SUBMITTER: Berger KI 

PROVIDER: S-EPMC6226396 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

altmetric image

Publications

Cardiopulmonary Exercise Testing Reflects Improved Exercise Capacity in Response to Treatment in Morquio A Patients: Results of a 52-Week Pilot Study of Two Different Doses of Elosulfase Alfa.

Berger Kenneth I KI   Burton Barbara K BK   Lewis Gregory D GD   Tarnopolsky Mark M   Harmatz Paul R PR   Mitchell John J JJ   Muschol Nicole N   Jones Simon A SA   Jones Simon A SA   Sutton V Reid VR   Pastores Gregory M GM   Lau Heather H   Sparkes Rebecca R   Shaywitz Adam J AJ  

JIMD reports 20171121


<h4>Objective</h4>To assess impact of a 52-week elosulfase alfa enzyme replacement therapy (ERT) on exercise capacity in Morquio A patients and analyze cardiorespiratory and metabolic function during exercise to uncover exercise limitations beyond skeletal abnormalities.<h4>Methods</h4>Morquio A patients aged ≥7 years, able to walk >200 m in the 6-minute walk test (6MWT), received elosulfase alfa 2.0 mg/kg/week (N = 15) or 4.0 mg/kg/week (N = 10) for 52 weeks in the randomized, double-blind MOR-  ...[more]

Similar Datasets

| S-EPMC8759989 | biostudies-literature
| S-EPMC4744659 | biostudies-literature
| S-EPMC5065598 | biostudies-literature
| S-EPMC4243006 | biostudies-literature
| S-EPMC4700045 | biostudies-literature
| S-EPMC5298029 | biostudies-literature
| S-EPMC6047108 | biostudies-literature
| S-EPMC5604956 | biostudies-literature
| S-EPMC5442692 | biostudies-literature
| S-EPMC4206772 | biostudies-literature